ArticleBMC gastroenterology2025
Irisin prevents liver injury during exhausting physical activity by suppressing ferroptosis via Nrf2/GPX4 signaling.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The role of exercise in MFN2 regulation in osteoarthritis.Molecular biology reports · 2026Review
- Exercise Impacts Liver Disease: Balancing Metabolic and Immune Homeostasis.International journal of biological sciences · 2026Review
- The AST/ALT ratio as a mediator of heavy metal exposure and diabetic kidney disease (DKD) risk: A NHANES study.Scientific reports · 2025Article
- Genetic Basis of the Antioxidant and Serum Enzyme Activities of the Large Yellow CroakerAntioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrisin, a recently identified protein that is released during exercise and promotes the transformation of white adipocytes into brown adipocytes. The expression of irisin in the liver suggests its possible involvement in liver function and performance, however it has not been comprehensively investigated.
methodsThe investigation included creating exhaustive exercise (EE) models using 8-week-old C57BL/6 mice. Following exhaustion exercise, irisin was administered intraperitoneally on a daily basis. The liver damage was assessed by HE staining and by measuring the levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). The impact of irisin on liver inflammation levels during EE was assessed using ELISA and qRT-PCR. The impact of irisin on ferroptosis was assessed by measuring the levels of GSH (glutathione), GPX4 (glutathione peroxidase 4), MDA (malondialdehyde), and Fe
resultsThis research discovered that EE resulted in liver damage, disruption of liver cell organization, increased levels of ALT and AST enzymes (all P < 0.001), and raised levels of inflammatory cytokines and chemokines (all P < 0.001). Simultaneously, EE triggered hepatic ferroptosis, as evidenced by elevated levels of ROS (reactive oxygen species) (P < 0001), Fe
conclusionThese findings indicate that irisin has the ability to safeguard the liver from damage caused by intense exercise by suppressing ferroptosis triggered by the Nrf2/GPX4 signaling pathway and reducing the inflammatory response after oxidative stress. These results provide novel perspectives on the correlation between irisin and liver disease.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.